| Quantitative phosphoproteomics reveals extensive protein phosphorylation dysregulation in the cerebral cortex of Huntington’s disease mice prior to onset of symptoms I Mees, H Tran, A Roberts, L Lago, S Li, BR Roberts, AJ Hannan, T Renoir Molecular Neurobiology 59 (4), 2456-2471, 2022 | 14 | 2022 |
| Phosphoproteomic dysregulation in Huntington’s disease mice is rescued by environmental enrichment I Mees, S Li, H Tran, CS Ang, NA Williamson, AJ Hannan, T Renoir Brain Communications 4 (6), fcac305, 2022 | 7 | 2022 |
| Implications of tau dysregulation in Huntington’s disease and potential for new therapeutics I Mees, RM Nisbet, AJ Hannan, T Renoir Journal of Huntington's Disease 12 (1), 1-13, 2023 | 5 | 2023 |
| Loss-of-function and gain-of-function studies refute the hypothesis that tau protein is causally involved in the pathogenesis of Huntington’s disease I Mees, S Li, LC Beauchamp, KJ Barnham, M Dutschmann, AJ Hannan, ... Human Molecular Genetics 31 (12), 1997-2009, 2022 | 3 | 2022 |
| Phosphoproteomics implicates glutamatergic and dopaminergic signalling in the antidepressant-like properties of the iron chelator deferiprone V Uzungil, S Luza, CM Opazo, I Mees, S Li, CS Ang, NA Williamson, ... Neuropharmacology 246, 109837, 2024 | | 2024 |
| Experience-dependent modulation of neurodegenerative disorders: Huntington’s disease as an exemplar I Mees, H Tran, T Renoir, AJ Hannan Degenerative Disorders of the Brain, 116-142, 2019 | | 2019 |
